We are excited to announce the first close of our seed funding round for £1.6M to accelerate the development of our self-learning AI for digital pathology. A huge thank you to TwinPath Ventures, Scottish Enterprise, and the University of Glasgow for your confidence in our vision and your incredible support. We’re ready to scale: turning raw medical imagery into actionable clinical intelligence and a powerful new engine for drug discovery and development. 🔬✨ 🔗 Read the full story here:
TileBio
Biotechnology Research
Glasgow, Scotland 350 followers
Building AI Foundation Models for Better Cancer Care
About us
At Tile, we are pioneering the future of cancer diagnostics with our cutting-edge AI technology. By combining expertise in computer science, diagnostic histopathology, cancer surgery, and molecular medicine, we are developing foundation models for all pathology. Our self-learning AI processes images of tumour tissue into a proprietary “language of cancer”. Combined with our large language model, we can understand cancer samples without human labels to detect cancer more accurately and earlier, ultimately improving patient outcomes. Anchored in world-leading research institutions like Cancer Research UK and the University of Glasgow, we are committed to transforming cancer care through innovation and collaboration. Join us on our journey to revolutionise cancer care. Learn more at tilebio.com.
- Website
-
https://tilebio.com
External link for TileBio
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Glasgow, Scotland
- Type
- Public Company
- Founded
- 2025
- Specialties
- Pathology, Deep Learning, AI, Cancer, Clinical Trial Stratification, Biomarker Validation, and Biomarker Target Discovery
Locations
-
Primary
Get directions
Glasgow, Scotland, GB
Employees at TileBio
Updates
-
We are humbled to be shortlisted for the 2026 Scotland’s Life Sciences Awards. The quality of submissions this year was exceptional, and we feel very fortunate to be in such good company with the other nominees. This recognition would not have been possible without our vital collaboration with NHS Greater Glasgow and Clyde and the West of Scotland Innovation Hub. We are immensely grateful for their support; we wouldn't be where we are today without them. Congratulations to all our fellow finalists, your work inspires us! See you all at the Awards Dinner in March. #LifeSciencesScotland #ScottishInnovation #NHSGGC
A huge thank you to everyone who submitted entries for the 2026 Scotland’s Life Sciences Awards. This has been an outstanding year for submissions, both in volume and calibre. Congratulations to all of our finalists, your work represents the strength and ambition of Scotland’s life sciences sector. For the full list of finalists, click here: https://lnkd.in/eT_jBAQv Tickets are available for both the Scotland’s Life Sciences Conference and the Awards Dinner. Tickets are limited, so don’t miss out on a full day of insight, connection and an evening celebrating excellence across the sector. For tickets and further information, click here: https://lnkd.in/eEyXz5Cd We can’t wait to celebrate with everyone in March.
-
Another fantastic #DigiPathLondon conference. I always look forward to hearing about the latest developments in this space, and this year I was thankful to deliver an update on the self-supervised tissue-language foundation model TileBio has been developing. Big thank you to the conference organisers for inviting me to speak, and to Dimitra Pouli, MD PhD EMBA for chairing the session. Looking forward to next year already.
-
-
Excited to announce TileBio’s new partnership with Terrain Life Science. By uniting Terrain’s cutting-edge spatial proteomics with our AI foundation model for digital pathology, we’re creating next-generation tools to unlock new biomarkers and accelerate precision medicine. Read the full release here 👉
-
We’re raising a £2M seed round to scale TileBio’s foundation model of pathology and expand our team. By learning directly from raw pathology slides, our AI discovers its own vocabulary of tissue morphology, unlocking new tools for cancer triage, biomarker discovery, and clinical trials. With NHS-backed data access and a world-class founding team, we’re building the operating system of pathology to power the next generation of diagnostics and drug discovery. 👉 Read more about our vision and seed round here: https://lnkd.in/eQA_SvZJ